Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJ).
Conditions
Interventions
BC001+Sintilimab+XELOX
Locations
1
China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Start Date
February 28, 2025
Primary Completion Date
October 1, 2026
Completion Date
April 1, 2027
Last Updated
March 10, 2025
NCT06340711
NCT06078709
NCT05969860
NCT04389632
NCT04895709
NCT04704661
Lead Sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions